EGFR and non-small cell lung carcinoma: With the advent of precision medicine and personalized treatment strategies, the paradigm of targeting the epidermal growth factor receptor (EGFR) with tyrosine kinase inhibitors (TKIs) has become the standard of care for advanced NSCLC.